Clinical Trial Update: REbif FLEXible Dosing in Early Multiple Sclerosis (MS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating flexible dosing of REBIF (interferon beta-1a) in early multiple sclerosis. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2012-09-24